{"filings":[{"id":1204561,"accession_number":"0001104659-26-076648","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-06-23T12:00:37+00:00","items":["5.07"],"status":"ready","headline":"Novavax shareholders elect directors, approve say-on-pay by narrow margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees (Jacobs 43.5M, Alton 41.4M, Rodgers 42.6M) elected.","Advisory say-on-pay passed with 35.8M for vs 34.9M against, a narrow margin.","Amendment and restatement of 2015 Stock Incentive Plan approved (38.2M for, 32.6M against).","Amendment and restatement of 2013 ESPP approved (36.0M for, 33.9M against).","Ratification of Ernst & Young as auditor approved (72.9M for, 23.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90492,"accession_number":"0001628280-26-030924","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.","Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.","Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.","Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.","FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":139514000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100038,"accession_number":"0001000694-26-000011","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q4 net income $18M, full-year profit $440M; Pfizer Matrix-M license deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $147M (+67% YoY); net income $18M vs $81M loss in Q4 2024.","Full year 2025 revenue $1.12B (+65% YoY); net income $440M vs $187M loss in 2024.","Jan 2026: non-exclusive Pfizer license for Matrix-M in two areas; $30M upfront, up to $500M milestones plus royalties.","Cash $751M at Dec 2025 (down from $938M); Feb 2026 $330M credit facility from MidCap Financial, initial $50M draw.","Cost reductions exceed goals; 2026 Non-GAAP R&D+SG&A target $310-340M, falling to ≤$200M by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100037,"accession_number":"0001104659-26-004785","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).","Tiered high mid-single digit royalties on net sales until later of 20 years or patent expiry.","Non-exclusive worldwide license for up to two infectious disease fields; first field selected, second at Pfizer's option.","Pfizer controls development, manufacturing, and commercialization; separate supply agreements to be finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100036,"accession_number":"0001104659-26-002725","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Novavax presents strategic update at J.P. Morgan; 2025 results pending","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Preliminary financial results for year ended Dec 31, 2025 are being finalized and subject to change.","No specific financial metrics disclosed; presentation focuses on strategic and business updates.","Investor presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.","Company cautions that actual results may differ materially from preliminary data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116385,"accession_number":"0001000694-25-000048","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q3 net loss $202M, revenue down to $70M; raises FY2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $70M, down 18% YoY from $85M; product sales (Nuvaxovid) $0 vs $38M.","Net loss $202M vs $121M YoY; includes $97M asset impairment from Maryland site consolidation.","Cash $778M as of Sep 30, 2025; completed convertible debt refinancing extending maturities to 2031.","Sanofi milestones $225M YTD; $50M earned on marketing authorization transfers in Q4 2025.","Maryland site consolidation yields $60M cash proceeds, ~$230M cost savings over 11 years."],"consensus_eps_estimate":null,"consensus_eps_actual":2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":976340000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116384,"accession_number":"0001104659-25-105818","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.","Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.","Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.","Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.","CEO John C. Jacobs notes delivery on partnership obligations and future royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116383,"accession_number":"0001104659-25-101390","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","2.06","8.01","9.01"],"status":"ready","headline":"Novavax enters lease assignment and asset sales with AstraZeneca for $59.8M; expects Q3 non-cash charges of $125-127M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.","Non-cash impairment of $96-98M in Q3 2025 from these transactions, plus $29M from convertible note extinguishment.","Parcel sale closes Q4 2025; lease assignment and asset sale close Q1 2026.","Novavax pays base rent for Jan-Jun 2026 under lease assignment; AstraZeneca responsible thereafter.","Corporate headquarters relocated from 700 Quince Orchard Rd to 21 Firstfield Rd, Gaithersburg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116382,"accession_number":"0001104659-25-097317","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.","Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.","Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.","Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.","CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132828,"accession_number":"0001104659-25-084053","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Novavax issues $225M 4.625% convertible notes due 2031, exchanges $148.7M of 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $225M principal of 4.625% Convertible Senior Notes due 2031; initial conversion price ~$11.14 (27.5% premium).","Exchanged ~$175.3M of new notes for ~$148.7M of existing 5.00% 2027 notes; $49.7M for cash.","Notes mature Sept 1, 2031; interest payable semi-annually; redeemable by company after Sept 5, 2028 if stock >130% of conversion price.","Maximum dilution: 25,743,690 shares upon conversion at max conversion rate $8.74 per share.","Exchange portion unregistered under Section 3(a)(9); shares upon conversion also exempt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132827,"accession_number":"0001104659-25-084049","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.","Shelf life extended from 3 to 6 months for the 2025-2026 formula.","FDA requires two postmarketing studies: a Phase 3 safety/immunogenicity study and a Phase 4 placebo-controlled trial on post-COVID vaccination syndrome.","Sanofi to lead commercialization; Novavax receives tiered royalties on sales.","Clinical data show JN.1 strain induces immunity against multiple JN.1 lineage variants including NB.1.8.1 and XEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132826,"accession_number":"0001104659-25-081160","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Novavax issues $225M in 4.625% convertible notes due 2031, refinancing 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $225M of 4.625% Convertible Senior Notes due 2031; exchanged ~$148.7M of 2027 notes and raised ~$49.7M new cash.","Conversion price $11.14 per share, a 27.5% premium over the Aug 20 closing price of $8.74.","Approximately $26.5M of 2027 notes remain outstanding; net proceeds from subscription for general corporate purposes.","Closing expected on or about Aug 27, 2025; financial advisor JWCA plans to buy ~1.2M shares concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132825,"accession_number":"0001000694-25-000031","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.","Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.","Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).","Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.","Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses."],"consensus_eps_estimate":null,"consensus_eps_actual":3.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":905895000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149382,"accession_number":"0001104659-25-061874","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Novavax stockholders elect directors, approve advisory compensation, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Rachel K. King, John W. Shiver, and Charles W. Newton (each with majority 'For' votes).","Advisory vote on named executive officer compensation approved: 41,390,651 For, 15,830,308 Against.","Ratification of Ernst & Young as auditor for FY2025 approved: 79,306,893 For, 15,057,873 Against.","Quorum of 95,359,194 shares present; total outstanding shares were 161,968,503 as of record date April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149381,"accession_number":"0001104659-25-058379","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.","Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.","Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.","Novavax continues to pursue partnering opportunities to advance further development of these programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149380,"accession_number":"0001104659-25-052959","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Novavax eliminates COO role; John Trizzino to depart June 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO position eliminated; John Trizzino's employment terminated effective June 20, 2025.","Separation pay of $601,778 lump sum plus up to 12 months COBRA premiums.","Consulting agreement June 20 to Dec 31, 2025 at $15,000/month; equity continues vesting during period.","Unvested options from March 2023 grant will fully vest upon consulting agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149379,"accession_number":"0001104659-25-050226","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Novavax receives FDA approval for Nuvaxovid COVID-19 vaccine; triggers $175M Sanofi milestone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approves BLA for Nuvaxovid for COVID-19 in adults 65+ and high-risk individuals 12-64.","Approval triggers $175M milestone payment from Sanofi under May 2024 Collaboration and License Agreement.","FDA requests new Phase 4 postmarketing efficacy trial in 50-64 age group without high-risk conditions; Novavax working with Sanofi on funding.","Novavax reiterates FY2025 R&D+SG&A guidance of $475-525M; projects ~$350M for FY2026 and ~$250M for FY2027.","Expects commercial delivery of 2025-2026 COVID-19 vaccine formula in US this Fall with Sanofi, pending VRBPAC recommendation May 22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149378,"accession_number":"0001000694-25-000024","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.","Raises full-year adjusted total revenue framework to $975M-$1,025M (from $300-$350M).","FDA BLA review on track; approval triggers $175M milestone from Sanofi; MAs to Sanofi by Q4 2025.","Strengthened Takeda partnership: $20M upfront, annual milestones plus royalties on Japan sales.","SHIELD-Utah: Nuvaxovid recipients had ~39% fewer reactogenicity symptoms vs mRNA vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":666655000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149377,"accession_number":"0001104659-25-044372","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.","Annual $2M service fee plus $8M milestone if Takeda gets marketing approval; $5M of milestone creditable.","Profit share replaced with tiered royalty on net sales in mid-to-high teens, effective April 1, 2024.","Takeda may develop a different vaccine strain but must procure it from Novavax.","Parties also entered release agreement settling all claims related to original 2021 pact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149376,"accession_number":"0001104659-25-040656","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Novavax appoints Charles W. Newton to Board, increasing size to nine members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 9 members; Charles W. Newton appointed as Class III director effective April 25, 2025.","Newton receives initial equity grant of 42,840 stock options and 28,560 RSUs ($525,000 grant-date fair value).","Annual equity grants valued at $350,000 will begin after the 2026 Q2 board meeting.","Board affirms Newton qualifies as independent under Nasdaq standards; no related-party transactions.","Standard indemnification agreement to be entered with Novavax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149375,"accession_number":"0001104659-25-037728","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Novavax says COVID-19 vaccine BLA approvable; FDA requests additional clinical data as PMC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Believes BLA is approvable based on FDA conversations as of PDUFA date April 1 and through April 23.","Received formal FDA information request for a post-marketing commitment (PMC) to generate additional clinical data.","Intends to engage expeditiously with FDA to address the PMC and move to approval as soon as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149374,"accession_number":"0001104659-25-031099","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Novavax says FDA missed PDUFA deadline for COVID-19 vaccine BLA; still awaiting decision","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's April 1 PDUFA date passed; no official decision received as of April 2, 2025.","Novavax completed all FDA information requests and believes BLA is ready for approval.","Phase 3 data cited showing vaccine is safe and effective for COVID-19 prevention.","Company positions its vaccine as an attractive alternative to mRNA COVID-19 vaccines in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168448,"accession_number":"0001104659-25-022588","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Novavax Chair James Young retires; Margaret McGlynn named successor; John Shiver joins board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Young, PhD resigned as Board Chair effective March 10, 2025, after 15 years on the board.","Margaret McGlynn, former Merck Vaccines president, appointed as Chair of the Board.","John Shiver, PhD appointed as independent director; has 30+ years vaccine/RNA experience.","Shiver receives initial equity grant of 35,770 options and 23,480 RSUs.","No disagreement cited; changes part of planned board succession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168447,"accession_number":"0001104659-25-022435","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Novavax terminates Canada COVID vaccine APA, to recognize $576M revenue in Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Canada terminated APA effective March 7, 2025, citing Novavax's failure to obtain regulatory approval for vaccine from Biologics Manufacturing Centre by Dec 31, 2024.","Novavax expects to recognize $576M previously in deferred revenue and other liabilities as product revenue in Q1 2025.","$28M in advance payments must be refunded to Canada within 30 days of the termination notice.","$20M escrow related to an MOU may be released to Novavax as the MOU is no longer feasible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168446,"accession_number":"0001104659-25-020023","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novavax issues 2025 financial guidance and strategic update at TD Cowen conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Provided 2025 revenue framework and combined R&D/SG&A expense guidance for 2025 and 2026.","Reaffirmed transition of COVID-19 vaccine commercialization to Sanofi starting 2025-2026 season.","Highlighted clinical progress on COVID-19, CIC, and standalone flu vaccine candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168445,"accession_number":"0001000694-25-000006","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax reports Q4 revenue $88M, net loss $81M; transitions COVID vaccine to Sanofi; guides 2025 adj revenue $300-350M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $88M (vs $291M YoY); full year $682M (vs $984M). Product sales $50M vs $251M.","Net loss narrowed to $81M in Q4 (vs $178M); full year loss $187M (vs $545M). Cash $938M at Dec 31, 2024.","Transitioned Nuvaxovid commercial lead to Sanofi for 2025-2026 season. BLA target action date April 2025; $175M milestone upon approval.","Sold Czech facility to Novo Nordisk for $200M; gain of $52M, annual cost savings ~$80M.","2025 guidance: combined R&D+SG&A $475-525M; adjusted licensing/royalties/other revenue $300-350M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":682162000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168444,"accession_number":"0001104659-25-002863","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Reaffirmed full year 2024 financial guidance, no specific figures provided.","Preliminary expectations for combined R&D and SG&A expenses for 2025 and 2026 mentioned without numbers.","Presenting strategic updates at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185578,"accession_number":"0001104659-24-132569","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Novavax completes $200M sale of Czech manufacturing campus to Novo Nordisk","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $200M; $180M cash at close, $10M paid Sept 2024, $10M escrow for 12 months.","Seller also received ~$2.6M reimbursement for operating costs between Dec 3 and closing.","Novavax sold its Bohumil, Jevany facility including land, movable assets, contracts, and employees.","Transaction closed Dec 30, 2024; Novo Nordisk Production Czech s.r.o. is the purchaser."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185577,"accession_number":"0001104659-24-129823","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax amends Australia COVID vaccine agreement; cancels doses, credits $31M, extends to 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment #5 cancels certain COVID vaccine doses scheduled for delivery Q4 2023 through Q4 2025.","Approximately $31M of advanced payment credited against outstanding invoices and future delivery of ~3M doses.","Updated delivery schedule allows potential delivery of vaccine through end of 2029.","Commonwealth granted remedies for missed deliveries, regulatory approval failures, or notification lapses.","No additional cash payments required for future doses under the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185576,"accession_number":"0001104659-24-125265","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax subsidiary agrees to sell Czech manufacturing campus to Novo Nordisk subsidiary for $200M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $200M; $10M credit from September 2024 and $10M escrow released 12 months post-closing.","Closing conditioned on Czech drug regulator modifying Novavax CZ's manufacturing authorization to reduce scope.","Novavax CZ continues operations; purchaser reimburses operating costs up to $3.5M per month until closing.","Customary indemnification; termination right if condition not satisfied within 4 months of signing.","Transaction involves transfer of land, equipment, contracts, and employees at Bohumil, Jevany facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185575,"accession_number":"0001104659-24-120698","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novavax to present corporate update at Jefferies London Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation scheduled for November 20, 2024; no specific numbers or details included in the filing or attached exhibit.","Form 8-K and Exhibit 99.1 contain only forward-looking cautionary language and generic strategic update references.","No financial guidance, partnership announcements, or operational metrics provided in the furnished materials.","Investors directed to company website for full presentation materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185574,"accession_number":"0001104659-24-116593","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Novavax's COVID-flu combo and standalone flu vaccines","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed clinical hold on Novavax's IND for CIC and stand-alone influenza candidates on Nov 11.","Hold was placed Oct 16 due to a serious adverse event (motor neuropathy, later ALS) in a Phase 2 participant.","Novavax provided additional data confirming the event was not related to the vaccine.","FDA cleared Novavax to begin enrollment in the planned Phase 3 trial for both vaccine candidates.","Novavax will work with investigators to resume trial activities as quickly as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185573,"accession_number":"0001000694-24-000040","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.","FDA removed clinical hold on COVID-19-influenza combination and stand-alone influenza IND candidates.","Full-year 2024 revenue guidance cut to $650-700M from $700-800M; product sales now $175-225M.","Combined R&D/SG&A spend on track; targeting ~$500M in 2025 and ~$350M in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":593851000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185572,"accession_number":"0001104659-24-114376","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Novavax settles UK COVID vaccine supply dispute, agrees to pay $123.8M refund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with UK Health Security Agency resolves all claims related to the Amended and Restated Supply Agreement.","Company to pay $123.8M in equal quarterly installments of $10.3M over three years, ending June 30, 2027.","First installment of $10.3M due November 30, 2024 under a Letter of Amendment.","Total includes $11.3M imputed interest; company may avoid interest by accelerating payments.","Original supply agreement terminated effective November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185571,"accession_number":"0001104659-24-108950","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on Novavax's combo COVID-flu and standalone flu vaccines after motor neuropathy SAE","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on Novavax's IND for CIC and standalone influenza vaccine candidates.","Hold triggered by spontaneous report of serious adverse event: motor neuropathy in a single Phase 2 participant.","Participant received vaccine Jan 2023; trial completed Jul 2023; SAE reported Sep 2024.","Clinical hold may delay initiation of Phase 3 immunogenicity trial for CIC and influenza vaccine.","COVID-19 IND for Novavax's COVID-19 vaccine is not impacted by the clinical hold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185570,"accession_number":"0001104659-24-105533","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Novavax clarifies it has not updated FY2024 guidance after analyst report","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Analyst report published Oct 1, 2024 cited management discussions on US COVID-19 vaccine market.","Novavax has not updated or reaffirmed its full year 2024 guidance issued August 8, 2024.","Company expects US COVID-19 vaccination market for 2024-2025 season to be similar to last year.","No change to previously issued FY2024 guidance; no new financial information provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202155,"accession_number":"0001000694-24-000037","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q2 net income $162M on $415M revenue; Sanofi partnership boosts cash to $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenue $415M (vs. $424M Q2 2023); net income $162M (vs. $58M).","Received $500M upfront + $70M equity from Sanofi; eligible for up to $700M in milestones plus royalties.","Ended Q2 with $1.1B cash vs. $584M Dec 2023; combined R&D and SG&A down 34% YoY.","Filed EUA amendment with FDA for 2024-2025 formula COVID-19 vaccine; BLA accepted with PDUFA April 2025.","Targeting FY2025 combined R&D/SG&A below $500M; Phase 3 combo/flu vaccine trial starts Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":509339000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218212,"accession_number":"0001104659-24-071735","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Novavax stockholders approve director elections, advisory pay, and equity plan share increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Class II directors Richard Douglas, Margaret McGlynn, and David Mott with majorities (approx. 25.5M, 22.9M, 23.1M For).","Advisory vote on 2023 executive compensation passed: 24.2M For, 8.7M Against, 11.0M Abstain.","Amended 2015 Stock Incentive Plan approved (22.4M For, 20.9M Against), adding 6.5M shares to the pool.","Amended 2013 Employee Stock Purchase Plan approved (23.2M For, 10.0M Abstain), adding 1M shares with annual increase formula.","Ratification of Ernst & Young as auditor for FY2024 passed overwhelmingly (69.0M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218211,"accession_number":"0001104659-24-068875","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novavax FDA sets PDUFA date April 2025 for COVID vaccine BLA; plans EUA sales for 2024-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA completed BLA filing review; PDUFA goal date set for April 2025 for COVID-19 vaccine.","Company to sell COVID-19 vaccine under EUA for 2024-2025 season in U.S.","Plans to initiate pivotal Phase 3 trial for COVID-Influenza Combination (CIC) in H2 2024.","Targeting updated single-dose vial COVID vaccine for 2024-2025 season; possible combo vaccine launch in 2026.","Continuing global restructuring and cost reduction plan to manage cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218210,"accession_number":"0001104659-24-064680","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Novavax President of R&D Filip Dubovsky to retire effective June 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dubovsky retires as President, R&D effective June 30, 2024.","Will provide consulting services for 12 months post-retirement at $15,000/month.","Company will pay COBRA premiums for up to 11 months.","Equity awards continue to vest during consulting period; unexercised options exercisable 90 days after.","Non-competition and non-solicitation covenants commence upon retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218209,"accession_number":"0001104659-24-060444","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Novavax and Sanofi enter $500M upfront collaboration; Sanofi buys $68.8M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$500M non-refundable upfront payment; up to $700M in milestones for COVID products.","Additional milestones up to $200M per Adjuvant Product (first four); royalties mid-single to low-twenties percent.","Sanofi acquires 6.88M shares at $10/share (~$68.8M) in private placement.","Sanofi gets co-exclusive rights to commercialize Novavax's COVID vaccines globally from 2025/2026 season."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218208,"accession_number":"0001104659-24-059659","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax signs $1.3B Sanofi deal; Q1 revenue $94M, net loss $148M; removes going concern","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Co-exclusive licensing with Sanofi includes $500M upfront, ~$70M equity, up to $700M milestones plus royalties per product.","Q1 2024 revenue $94M (up from $81M YoY), net loss $148M (improved from $294M loss YoY).","Reduced current liabilities by $831M in Q1; removed going concern notice.","Updated 2024 guidance: Combined Revenue & Sanofi Payments $970M-$1,170M; Total Revenue $400M-$600M.","Added standalone influenza arm to Phase 3 COVID-Flu combo trial; on track for H2 2024 initiation, potential 2026 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218207,"accession_number":"0001000694-24-000013","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Novavax reduces stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Amended and Restated By-Laws effective April 22, 2024.","Quorum reduced from majority of outstanding shares to one-third (33 1/3%) of shares entitled to vote.","Change aimed at mitigating past quorum failures caused by dispersed stockholder base and broker non-voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238182,"accession_number":"0001104659-24-039006","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax settles manufacturing dispute with Fujifilm for $42M, releases claims","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Paid $42M on March 25, 2024 to Fujifilm, resolving $68.6M disputed installments under prior cancellation agreement.","Mutual release of all claims; Fujifilm agreed to dismiss pending arbitration from October 2023.","Original liability under Prior SAR was up to $185 million; settlement removes uncertainty and potential larger payout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238181,"accession_number":"0001000694-24-000009","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).","Full-year 2023 net loss $545M vs $658M in 2022; operating expenses cut 41% ($1.1B reduction).","Cash $584M at Dec 31, 2023, down from $1.3B a year earlier; raised $110M via ATM offerings in Q4.","FY2024 guidance: total revenue $800M-$1B, combined R&D+SG&A $700-$800M; Q1 2024 revenue expected ~$100M.","Announced Gavi settlement; plan to start Phase 3 COVID-flu combo trial in H2 2024 with potential 2026 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":983705000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238180,"accession_number":"0001104659-24-026225","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Novavax settles Gavi arbitration: pays $75M upfront, $400M deferred through 2028","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Initial cash payment of $75M to Gavi made Feb 20; deferred payments of $80M/yr through 2028 total $400M.","Deferred payments may be reduced by annual vaccine credits for qualifying sales to low-income countries.","Gavi receives security interest in accounts receivable from Serum Institute of India under Matrix-M supply agreement.","Settlement terminates the May 2021 Advanced Purchase Agreement and ends related arbitration proceedings.","Novavax may price vaccines for qualifying countries in its discretion; credit applied at actual price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238179,"accession_number":"0001000694-24-000003","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Novavax to cut ~12% of global workforce; expects $4-7M restructuring charge in Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved ~12% global workforce reduction (9% of FTEs; remainder contractors/consultants).","One-time severance and benefit charge estimated at $4M to $7M, primarily in Q1 2024.","Resulting workforce expected to be ~30% lower vs. end of Q1 2023.","Full annual cost savings expected in 2025; ~85% of annual impact realized in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238178,"accession_number":"0001104659-24-002100","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.","Preliminary data as company finalizes 2023 financial results; Ernst & Young not audited.","Update provided at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.","Additional material information expected in final financial statements; caution against undue reliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":983705000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255640,"accession_number":"0001104659-23-123481","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Novavax reaches $47M settlement in principle to resolve securities class action","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company agreed to pay $47M into settlement fund; expects D&O insurance to fund it.","Settlement resolves surviving claims about alleged false statements on vaccine manufacturing and regulatory approval.","Class period: February 24, 2021 to October 19, 2021; court approval required.","Settlement includes customary releases and a disclaimer of liability by Novavax and named executives.","Previously, court dismissed some claims but allowed others to proceed; parties now seek to end litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255639,"accession_number":"0001104659-23-119546","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Novavax appoints John Trizzino as President & COO; Herrmann to retire, Casey to join as CLO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Trizzino appointed President and COO (new role), effective November 20, 2023; base salary increased by $50k to $570,000.","John Herrmann to retire as Chief Legal Officer and Corporate Secretary, effective December 8, 2023.","Mark Casey to succeed Herrmann as Chief Legal Officer and Corporate Secretary, effective December 11, 2023.","Herrmann to serve as Senior Advisor under consulting agreement; monthly fee of $44,167 through December 10, 2024, with equity treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1823618819.502868,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-17T23:59:59+00:00|255639"}